HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Vertex has a new commercial head for ex-US activites, as the company aims to resolve a pricing row with UK health officials.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.

Vertex has become the latest big pharma company to acknowledge the potential of machine learning in drug development, announcing a three-year collaboration with the UK’s Genomics plc to use ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $456 from $476 and keeps an Equal ...

Vertex Pharmaceuticals has a new drug called suzetrigine that it says is nonaddictive and would offer an alternative to painkillers such as oxycodone. The company’s application is pending before the ...

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell disease and transfusion-dependent beta thalassemia.